Current Report Filing (8-k)
March 21 2019 - 4:32PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported)
March 18, 2019
BIOSCRIP,
INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
001-11993
|
05-0489664
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(Employer Identification Number)
|
1600 Broadway, Suite 700, Denver, Colorado
80202
(Address of principal executive offices)
(720) 697-5200
(Registrant's telephone number, including
area code)
Not applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 5.02 Departure of Directors or
Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 18, 2019, Jody Kepler provided
notice to BioScrip, Inc. that she will be stepping down as Senior Vice President, Chief Compliance Officer and Privacy Officer
of BioScrip, Inc. to become regulatory counsel of a healthcare company not in the infusion services field. Ms. Kepler is expected
to remain in her position until April 12, 2019 to assist with the transition of her duties.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
BIOSCRIP, INC.
|
|
|
|
|
|
|
|
|
Date: March 21, 2019
|
By:
|
/s/ Kathryn M. Stalmack
|
|
|
|
Kathryn M. Stalmack
|
|
|
|
Senior Vice President, General Counsel and Secretary
|
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Apr 2023 to Apr 2024